Russell Esterline

Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trial

Mikhail Kosiborod, Russell Esterline, Remo H.M. Furtado et al. · The Lancet Diabetes & Endocrinology · 2021 · 235 citations · Full text

Cardiovascular Disease, Cardiometabolic Risk, Cardiovascular Pharmacology +11

Reversible and irreversible inhibition of hepatic mitochondrial respiration by acetaminophen and its toxic metabolite, N-acetyl-p-benzoquinoneimine (NAPQI)

Russell Esterline, Sidhartha D. Ray, Sungchul Ji · Biochemical Pharmacology · 1989 · 75 citations

Pharmacological Study, Biochemistry, Mitochondrial Function +12

Effects of 6 weeks of treatment with dapagliflozin, a sodium‐glucose co‐transporter‐2 inhibitor, on myocardial function and metabolism in patients with type 2 diabetes: A randomized, placebo‐controlled, exploratory study

Jonas Oldgren, Sanna Laurila, Axel Åkerblom et al. · Diabetes Obesity and Metabolism · 2021 · 61 citations · Full text

Effects of the SGLT2 Inhibitor Dapagliflozin on Energy Metabolism in Patients With Type 2 Diabetes: A Randomized, Double-Blind Crossover Trial

Yvo J.M. Op den Kamp, Marlies de Ligt, Bas Dautzenberg et al. · Diabetes Care · 2021 · 57 citations · Full text

Characterization of the oxidant generation by inflammatory cells lavaged from rat lungs following acute exposure to ozone

Russell Esterline, David Bassett, Michael A. Trush · Toxicology and Applied Pharmacology · 1989 · 46 citations